Use of record linkage to evaluate treatment outcomes and trial eligibility in a real-world metastatic prostate cancer population in Scotland.
Kelly BaillieTanja MuellerJiafeng PanJennifer LaskeyMarion BennieChristine CrearieKimberley KavanaghSamantha Alvarez-MadrazoDavid MorrisonJulie ClarkeAileen KeelDavid CameronOlivia WuAmanj KurdiRobert J JonesPublished in: Pharmacoepidemiology and drug safety (2020)
Poorer prognostic features of non-trial eligible patients impact real-world outcomes of cancer medicines. Electronic record linkage of routinely collected healthcare data offers an opportunity to report outcomes on cancer medicines at scale and describe population demographics. The availability of such observational data to supplement clinical trial results enables patients and clinicians to make more informed treatment decisions, and policymakers to contextualise trial findings.
Keyphrases
- clinical trial
- prostate cancer
- healthcare
- end stage renal disease
- study protocol
- phase iii
- ejection fraction
- phase ii
- newly diagnosed
- prognostic factors
- squamous cell carcinoma
- small cell lung cancer
- randomized controlled trial
- genome wide
- type diabetes
- palliative care
- human immunodeficiency virus
- cross sectional
- open label
- young adults
- radical prostatectomy
- hiv testing
- hepatitis c virus
- adipose tissue
- antiretroviral therapy
- deep learning
- high density